A rapid progress in the development of novel and efficient anticancer drugs

Quote of the day Maybe… there aren't any such things as good friends or bad friends — maybe there are just friends, people who stand by you when you're hurt and who help you feel not so lonely. Maybe they're always worth being scared for, and hoping for, and living for. Maybe worth dying for, too, if that's what has to be. No good friends. No bad friends. Only people you want, need to be with; people who build their houses in your heart. ~ Stephen King ~

CANCER HELP ONLINE: CAR T-Cell Therapy Approved for Some Children and...

CANCER HELP ONLINE:
CAR T-Cell Therapy Approved for Some Children and...: CAR T-Cell Therapy Approved for Some Children and Young Adults with Leukemia https://www.cancer.gov/news-events/cancer-currents-blog/201...

CAR T-Cell Therapy Approved for Some Children and Young Adults with Leukemia

https://www.cancer.gov/news-events/cancer-currents-blog/2017/tisagenlecleucel-fda-childhood-leukemia

Treatment Beyond Progression With Immune Checkpoint Inhibitors—Known Unknowns

http://jamanetwork.com/journals/jamaoncology/fullarticle/2634499?utm_source=twitter&utm_campaign=content-shareicons&utm_content=article_engagement&utm_medium=social&utm_term=070617#.WV44Jl68vng.twitter

CANCER HELP ONLINE: Androgen Blockade and Salvage ­Radiation Therapy i...

CANCER HELP ONLINE: Androgen Blockade and Salvage ­Radiation Therapy i...: Androgen Blockade and Salvage ­Radiation Therapy in Prostate Cancer: Cautious Optimism Amid Unanswered Questions http://www.ascopost.com...

Androgen Blockade and Salvage ­Radiation Therapy in Prostate Cancer: Cautious Optimism Amid Unanswered Questions

http://www.ascopost.com/issues/june-10-2017/androgen-blockade-and-salvage-radiation-therapy-in-prostate-cancer-cautious-optimism-amid-unanswered-questions/

The recent report of results of RTOG 9601 by Shipley et al in The New England Journal of Medicine—reviewed in this issue of The ASCO Post—strongly supports the variably used practice of adding “androgen blockade” to salvage radiation therapy in men with a rising prostate-specific antigen (PSA) after radical prostatectomy. The findings show a clear reduction in prostate cancer–specific and overall mortality with the addition of 2 years of bicalutamide to salvage radiation therapy. Another likely (although not demonstrated) benefit is the reduction in the need to treat patients with subsequent life-long continuous or intermittent androgen blockade at the expense of treating all men with 2 years of bicalutamide.
RTOG 9601’s results further strengthen the growing concept that inhibition of androgen signaling can work in synergy with radiotherapy by inhibiting DNA repair and functioning as a potent radiosensitizer.These data are consistent with the large number of trials in intermediate- and high-risk localized prostate cancer in which the addition of androgen suppression to radiotherapy improved overall survival. However, one should be cautious about extrapolating all methods of androgen blockade as equal, as one of the only trials of radiotherapy in localized prostate cancer that did not show a benefit from androgen blockade was when bicalutamide monotherapy was used.

Intertumoral Heterogeneity within Medulloblastoma Subgroups

http://www.cell.com/cancer-cell/fulltext/S1535-6108(17)30201-5

CANCER HELP ONLINE: Our thoughts and prayers are with Mexico, speciall...

CANCER HELP ONLINE: Our thoughts and prayers are with Mexico, speciall...: Our thoughts and prayers are with Mexico, specially our colleagues, their friends & families.

Our thoughts and prayers are with Mexico, specially our colleagues, their friends & families.